Related Experiment Video

Updated: Aug 21, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aldosterone blockade in heart failure

Allan D Struthers1

  • 1Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. a.d.struthers@dundee.ac.uk

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 5, 2004
PubMed

Insights

Aldosterone blockade, using drugs like spironolactone and eplerenone, significantly reduces mortality risk in heart failure patients. These aldosterone antagonists are crucial for managing severe heart failure and post-myocardial infarction complications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Aldosterone significantly contributes to heart failure pathophysiology.
  • Standard treatments like ACE inhibitors may not fully suppress aldosterone.
  • Unchecked aldosterone promotes adverse cardiac remodeling and dysfunction.

Purpose of the Study:

  • To evaluate the efficacy of aldosterone blockade in heart failure.
  • To assess the impact of spironolactone and eplerenone on patient outcomes.

Main Methods:

  • The Randomized Aldactone Evaluation Study (RALES) compared spironolactone to placebo in severe heart failure.
  • The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) compared eplerenone to placebo in post-MI patients with LV dysfunction.

Main Results:

  • Spironolactone reduced all-cause mortality by 30% and cardiac mortality by 31% in RALES.
  • Eplerenone reduced all-cause mortality by 15% and cardiovascular events by 13% in EPHESUS.
  • Both studies showed significant reductions in cardiac and sudden death risks.

Conclusions:

  • Aldosterone blockade is a vital component of optimal heart failure therapy.
  • Spironolactone and eplerenone offer significant survival benefits.
  • Targeting aldosterone pathways improves outcomes in heart failure and post-MI patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...